Profit margins, US medicine supplies may get hit: Biocon |...

Profit margins, US medicine supplies may get hit: Biocon

Δημοσιευμένα

Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit margins and affect the affordability of generic medicines. With the US being its largest market, Biocon is strategizing to navigate the impact, considering factors like tariff rates and competitor responses. The company is also focusing on expanding its presence in Europe to mitigate risks.

Read Full Article

Παρακαλούμε συνδέσου στην Κοινότητά μας για να δηλώσεις τι σου αρέσει, να σχολιάσεις και να μοιραστείς με τους φίλους σου!